Ticker Launch
Sign inTry it free

IPO · VIRI

Dogwood Therapeutics, Inc.

Formerly Virios Therapeutics, Inc.; Virios Therapeutics, LLC

Dogwood Therapeutics, Inc. (VIRI) priced its initial public offering on Dec 18, 2020 at $10.00 per share, raising $30M, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $78.3M. ThinkEquity was lead-left underwriter. Duane Morris advised the company and Loeb & Loeb advised the underwriters.

Dogwood Therapeutics, Inc. is a development-stage biotechnology company developing antiviral therapies for conditions linked to a virus-triggered abnormal immune response, such as fibromyalgia. Its lead candidate, IMC-1, is a fixed-dose combination of famciclovir and celecoxib aimed at suppressing herpes simplex virus 1 activity.

Status
IPO
Ticker
VIRI
Exchange
Nasdaq Capital Market
Priced
Dec 18, 2020
IPO price
$10.00
Raised
$30M
Market cap at IPO price
$78.3M
First filed
Aug 28, 2020
Underwriters
ThinkEquity
Company counsel
Duane Morris
Underwriters' counsel
Loeb & Loeb
Sector
Biotech & pharma
Country / state
GA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.

More on this listing for subscribers

Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.

Try it free for 7 daysOpen in Ticker Launch

Then $99/month or $999/year. Cancel anytime.

Filings

Other Biotech & pharma IPOs in 2020